Haonan Li, Qiaorui He, Wenqing Zhu, Yanjun Zhang, Wangjia Pingcuo, Shikai Yu, Zhuoga Deji, Yi Zhang, Yifan Zhao
Heart Center, Shanghai Tenth People's Hospital, School of medicine, Tongji University, Shanghai, China.
Tongji University School of Medicine, Tongji University, Shanghai, China.
ESC Heart Fail. 2025 Jun;12(3):2148-2156. doi: 10.1002/ehf2.15232. Epub 2025 Jan 26.
We aim to elucidate the association of baseline eGFR and incident heart failure on patients receiving intensive BP treatment.
A post hoc analysis was conducted on the SPRINT database. Multivariab le Cox regression and interaction restricted cubic spline (RCS) analysis were performed to investigate the interaction between baseline eGFR and intensive BP control on heart failure prevention. The primary endpoint focused on incident heart failure. The study cohort comprised 8369 adults with a mean [SD] age of 68 [59-77] years, including 2940 women (35.1%). Over a median [IQR] follow-up period of 3.9 [2.0-5.0] years, 183 heart failure events were recorded. A significant interaction was observed between baseline eGFR and treatment groups in terms of heart failure prevention (Interaction P = 0.012). The risk of heart failure showed a sharp slope until eGFR = 75 mL/min/1.73 m and then became flat by an interaction RCS. Intensive BP treatment did not exhibit a preventive effect on heart failure (HR (95% CI) = 1.03 (0.82-1.52)) when baseline eGFR was 75 mL/min/1.73 m or lower. Conversely, when baseline eGFR was higher than 75 mL/min/1.73 m, a reduced risk of heart failure was observed (HR (95% CI) = 0.65 (0.41-0.98)). Intensive BP control did not increase the incident long-term dialysis regardless of baseline eGFR but was associated with a higher risk of eGFR reduction.
Among nondiabetic hypertensive patients, baseline eGFR serves as a crucial indicator for assessing the risk reduction potential of intensive BP control in heart failure prevention, with 75 mL/min/1.73 m appearing as a suitable cut-off value.
我们旨在阐明接受强化血压治疗患者的基线估算肾小球滤过率(eGFR)与新发心力衰竭之间的关联。
对收缩压干预控制不良预后试验(SPRINT)数据库进行事后分析。采用多变量Cox回归和交互作用受限立方样条(RCS)分析,以研究基线eGFR与强化血压控制在预防心力衰竭方面的相互作用。主要终点为新发心力衰竭。研究队列包括8369名成年人,平均[标准差]年龄为68[59 - 77]岁,其中女性2940名(35.1%)。在中位[四分位间距]随访期3.9[2.0 - 5.0]年期间,记录到183例心力衰竭事件。在预防心力衰竭方面,观察到基线eGFR与治疗组之间存在显著交互作用(交互作用P = 0.012)。心力衰竭风险在eGFR = 75 mL/min/1.73 m²之前呈陡峭斜率,之后通过交互作用RCS变得平缓。当基线eGFR为75 mL/min/1.73 m²或更低时,强化血压治疗对心力衰竭未显示出预防作用(风险比(95%置信区间)= 1.03(0.82 - 1.52))。相反,当基线eGFR高于75 mL/min/1.73 m²时,观察到心力衰竭风险降低(风险比(95%置信区间)= 0.65(0.41 - 0.98))。无论基线eGFR如何,强化血压控制均未增加长期透析的发生率,但与eGFR降低的较高风险相关。
在非糖尿病高血压患者中,基线eGFR是评估强化血压控制在预防心力衰竭中降低风险潜力的关键指标,75 mL/min/1.73 m²似乎是一个合适的临界值。